secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-08-30T23:59:59+00:00
Accession:  0001193125-24-211130
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics adopts amended indemnification agreements for directors and officers
--------------------------------------------------------------------------------

- Board approved amended form of indemnification agreement effective August 26, 2024.
- Revised change-of-control definition and added coverage of separate counsel expenses in change of control.
- Advancement of defense expenses clarified to be irrespective of insurance coverage.
- Includes express presumption of good faith in favor of Indemnitee (burden on challenger).
- Indemnitee may seek specific performance without showing irreparable harm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/0001193125-24-211130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/d703760d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-211130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer